PUR3100 was safe and all doses had fewer GI side effects compared to IV DHE
PUR3100 demonstrated a five-minute Tmax and Cmax within the targeted therapeutic range for all three doses tested
Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced successful completion of a Phase 1 trial evaluating safety and pharmacokinetics of PUR3100 in healthy volunteers. PUR3100 uses the Company's iSPERSE™ formulation technology to create an orally inhaled dry powder formulation of dihydroergotamine (DHE) for the treatment of acute migraine.
https://finance.yahoo.com/news/pulmatrix-announces-positive-top-line-140500360.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.